Viagra Study Involving Pregnant Women Halted Amid 11 Infant Deaths

Dutch researchers have pulled the plug on a Viagra study involving pregnant women, after the drug originally intended for treatment of erectile dysfunction may have played a part in the deaths of 11 infants. 

Researchers from Amsterdam Universitair Medische Centra (UMC) issued a press release (in Dutch) on July 23, announcing the immediate halt of the study, known as STRIDER, which was designed to evaluate whether Viagra (sildenafil) could improve fetal growth and birth outcomes in cases of severe restriction.

The study unexpectedly indicates that side effects of Viagra among pregnant women may be linked to the development of a blood vessel disease in the lungs, which can prove fatal after birth, according to the researchers.

The multinational, randomized clinical trial was initiated in 2015, with half of the pregnant women given a generic version of Viagra, and the other half given a placebo. At the time the Viagra study was halted, it involved about 183 women, half of whom were given the drug at centers in Amsterdam, the U.K., Canada, Australia and New Zealand.

Researchers said, however, that an interim analysis showed that Viagra increased the risk of both blood vessel disease in the lungs and the risk of death after birth, without showing any positive effects on fetal growth. The adverse effects actually made fetal outcomes worse, they determined.

As a result, the study has been stopped, and the expecting mothers have been told about the situation and whether they were given the placebo or Viagra, the researchers indicate. Children born to mothers who took the drug will be monitored.

Viagra is already prescribed “off-label” to some pregnant women to stimulate fetal growth, although that indication has not been approved by the FDA in the United States. While doctors are able to prescribe medications for any reason they believe is appropriate, researchers warn that the use of Viagra for this purpose should likely be stopped, based on the findings of this study.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications.
Suboxone lawyers will meet today with a federal judge, to discuss the status of thousands of tooth decay lawsuits brought over the opioid treatment film strips.
The MDL Judge will hear presentations from Depo-Provera lawyers seeking leadership positions during a two day hearing on March 13th and 14th, as a growing number of women continue to file brain tumor lawsuits against the makers of the popular birth control shot.